VEGFA and age-related macular degeneration: Although PDT-V is no longer used as first-line therapy for neovascular AMD, the appraisal of its role as adjunctive treatment to anti-VEGF drugs has not yet led to a harmonized decision-making process32,33,110, generating heterogeneous clinical data35–44,112 which could find meaning through a new personalized pharmacogenetic approach for PDT-V application that might be inclusive of fundus autofluorescence imaging to inspect RPE atrophy98–103 and optical coherence tomography angiography to decide on single or combined retreatment.